Sarepta’s Elevidys Sales Surge, But Next-Gen DMD Drug Platform Discontinued

Safety Scuttles SRP-5051, All Other PPMO Assets

 
• By Mandy Jackson
  
The rise in Elevidys sales did not push other Sarepta product sales down in Q3 (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Scrip